Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

NCT01963598 ↗

Phase 2 Completed 253 enrolled Regeneron Pharmaceuticals Sanofi · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, multicenter phase 2 study of the safety and efficacy of 3-month subcutaneous (SC) REGN1033 (SAR391786) treatment in patients with sarcopenia.

Timeline

Start: 2013-11
Primary completion: 2015-01
Completion: 2015-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Trevogrumab	Monoclonal antibody	—	Subcutaneous

Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

Summary

Timeline

Drugs

Indications